Company: BNBX
Filing Date: 2025-12-22
Form Type: S-1/A
Source: 0001104659-25-123402
Chunk: 22

Company: BNB PLUS CORP.
Filing Date: 2025-12-22
Form: S-1/A
Chunk 22
---
 IVT templates; (ii) LineaRNAP; and (iii) a proprietary IVT reaction buffer to simplify mRNA workflows and reduce dsRNA. The LineaIVT platform leverages our patented LineaRNAP’s DNA binding domain to chemically bind to chemically modified LineaDNA IVT templates, enabling the use of a proprietary IVT reaction buffer. Internal data shows that the LineaIVT system can reduce dsRNA contamination between 10x and 50x as compared to conventional system for the manufacture of mRNA while achieving equivalent or greater target mRNA yields. We believe the key advantages of the LineaIVT platform include:

| · | The                                                                                          
 reduction of dsRNA contamination resulting in higher target mRNA yields with the potential   
 to reduce downstream processing steps. dsRNA is a problematic immunogenic byproduct produced 
 during conventional mRNA manufacture;                                                        |

| · | delivery                                                                                   
 of LineaDNA IVT templates in as little as 14 days for milligram scale and 30 days for gram 
 scale;                                                                                     |

| · | reduced                                                                                      
 manufacturing complexities through single sourcing and potentially reduced mRNA purification 
 requirement to meet target quality standards; and                                            |

| · | potentially                                                                      
 enabling mRNA manufacturers to produce mRNA drug substance in less than 45 days. |

<div align='center'>9</div>

Recent Developments

Special Meeting of Stockholders

On December 12, 2025,
the Company held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders
approved (i) the issuance of shares of Common Stock upon exercise of the Crypto Pre-Funded Warrants and the Series E-2 Warrants,
in accordance with Nasdaq Listing Rules 5635(a) and 5635(d), (ii) an amendment to the Company’s certificate of incorporation
(the “Charter Amendment”) to increase the number of authorized shares of Common Stock from 200,000,000 to 500,000,000 and
(iii) an amendment to the Company’s 2020 Equity Incentive Plan to increase the number of authorized shares of Common Stock
reserved for issuance by 5,000,000 shares. The Company has discretion on whether and when to file the Charter Amendment and, as of the
date of this report, has made no decision.

Nasdaq Ticker Change; Amendments to Articles of Incorporation – Name Change

Effective October 7,
2025, the Company changed its ticker symbol on the Nasdaq